Redcare Pharmacy N.V.

As of June 30, 2026, Redcare Pharmacy N.V. carries a market capitalization of 1.27B, placing it among publicly traded companies globally. Its enterprise value stands at 1.50B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Redcare Pharmacy N.V.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Redcare Pharmacy N.V. has 20.18M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.43, and the price-to-book ratio stands at 3.00.

As of June 30, 2026, Redcare Pharmacy N.V. trades at an EV/EBITDA multiple of 27.53 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.51 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.50B versus a market cap of 1.27B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Redcare Pharmacy N.V. maintains a current ratio of 1.59, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 74.66, indicating elevated leverage, while an interest coverage ratio of 3.11 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Redcare Pharmacy N.V. posted a negative return on equity (ROE) of -8.70, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.51, reflecting losses generated across the asset base. The company generates approximately 1.16M in revenue per employee across its workforce of 2,553.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 13.46 indicates how many times Redcare Pharmacy N.V. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Redcare Pharmacy N.V. recorded an income tax benefit of -665,423.77 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -40.85M and -38.80M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 21, 2026, Redcare Pharmacy N.V.'s stock has declined approximately 7.44% over the past 52 weeks. The 50-day moving average sits at 61.22, while the 200-day moving average is 56.62.

Over the twelve months ended June 30, 2026, Redcare Pharmacy N.V. generated 2.97B in revenue and converted that into -38.80M in net income, yielding earnings per share of -1.99. EBITDA reached 54.52M, while operating income came in at -10.21M.

As of June 30, 2026, Redcare Pharmacy N.V. holds 109.73M in cash and equivalents against 327.36M in total debt, resulting in a net debt position of -69.22M. Total book value stands at 422.05M, with working capital of 187.44M providing operational flexibility.

Redcare Pharmacy N.V. produced -5.29M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -96.49M in capital expenditures, free cash flow totaled -101.78M - equivalent to -5.04 per share.

Over the twelve months ended June 30, 2026, Redcare Pharmacy N.V. posted a gross margin of 21.56, reflecting its pricing power and cost economics. The operating margin of -0.34 and net profit margin of -1.31 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -8.03: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 6.57, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Redcare Pharmacy N.V. shareholders.